Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

The PIK3CA Gene as a Mutated Target for Cancer Therapy

Author(s): John P. Gustin, David P. Cosgrove and Ben Ho Park

Volume 8, Issue 8, 2008

Page: [733 - 740] Pages: 8

DOI: 10.2174/156800908786733504

Price: $65

Abstract

The development of targeted therapies with true specificity for cancer relies upon exploiting differences between cancerous and normal cells. Genetic and genomic alterations including somatic mutations, translocations, and amplifications have served as recent examples of how such differences can be exploited as effective drug targets. Small molecule inhibitors and monoclonal antibodies directed against the protein products of these genetic anomalies have led to cancer therapies with high specificity and relatively low toxicity. Recently, our group and others have demonstrated that somatic mutations in the PIK3CA gene occur at high frequency in breast and other cancers. Moreover, the majority of mutations occur at three hotspots, making these ideal targets for therapeutic development. Here we review the literature on PIK3CA mutations in cancer, as well as existing data on PIK3CA inhibitors and inhibitors of downstream effectors for potential use as targeted cancer therapeutics.

Keywords: PIK3CA, mutation, oncogene, PI3 kinase, AKT, mTOR


Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy